SCHEMBL24173752

SCHEMBL24173752

Cc1cnc(-c2ccc(C(C)(C)C)cc2)n1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
HPGD P15428 3/20 0.50
HSD17B10 Q99714 3/20 0.50
KDM4E B2RXH2 2/20 0.50
POLB P06746 1/20 0.50
ALOX15 P16050 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
KIF11 P52732 2/20 0.47
SIGMAR1 Q99720 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
HTT P42858 3/20 0.41
DGAT1 O75907 2/20 0.40
TSHR P16473 1/20 0.40
TNKS O95271 1/20 0.38
PARP1 P09874 1/20 0.38
TNKS2 Q9H2K2 1/20 0.38
RECQL P46063 1/20 0.38
OPRD1 P41143 1/20 0.38
HSD11B1 P28845 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8989237 0.84 KIF11 (0.47) ALDH1A1HPGDHSD17B10KDM4EPOLB
SCHEMBL8989228 0.77 MAP4K4 (0.53) ALDH1A1SMN1; SMN2TSHRHSD11B1
SCHEMBL8453399 0.76 HPGDS (0.58) ALDH1A1HSD17B10KDM4ETDP1TSHR
SCHEMBL8989181 0.74 MAPT (0.51) ALDH1A1HPGDHSD17B10KDM4EALOX15
SCHEMBL22845298 0.73 POLB (0.45) ALDH1A1HPGDHSD17B10KDM4EPOLB
SCHEMBL14006037 0.72 ALDH1A1 (0.51) ALDH1A1HPGDHSD17B10KDM4EPOLB
SCHEMBL10176272 0.70 KIF11 (0.47) ALDH1A1HPGDHSD17B10KDM4EPOLB
SCHEMBL18520834 0.70 ALDH1A1 (0.50) ALDH1A1HPGDHSD17B10KDM4EPOLB
SCHEMBL17752219 0.70 ALDH1A1 (0.46) ALDH1A1HPGDHSD17B10KDM4EPOLB
SCHEMBL1544151 0.69 ALDH1A1 (0.49) ALDH1A1HPGDHSD17B10KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL ALDH1A1 648/4885HPGD 1777/4885HSD17B10 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.